SCLX Live signals | Maximize Profits with Getagraph.com

SELL 109340 min ago

@ $1.570

Issued: 13 Feb 2024 @ 16:00

Return: -42.45%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -2.45 %

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 15:20):

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain...

Stats
Today's Volume	324 497
Average Volume	1.03M
Market Cap	150.17M
EPS	$0 ( 2024-03-12 )
Next earnings date	( $-0.140 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.710
ATR14	$0.00100 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-22	Ma Stephen Hoi	Sell	0	Common Stock
2023-10-04	Ji Henry	Buy	200 000	Nonstatutory Stock Option (right to buy)
2023-10-04	Shah Jaisim	Buy	200 000	Nonstatutory Stock Option (right to buy)
2023-10-04	Wu Yue Alexander	Buy	250 000	Nonstatutory Stock Option (right to buy)
2023-10-04	Chun Jay	Buy	250 000	Nonstatutory Stock Option (right to buy)

INSIDER POWER
-85.42
Last 48 transactions
Buy: 17 843 347 \| Sell: 160 710 385

Volume Correlation

Long: 0.15 (neutral)

Short: 0.53 (weak)

Signal:(83.499) Neutral

Scilex Holding Company Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Scilex Holding Company Correlation - Currency/Commodity

0.00
( neutral )

0.06
( neutral )

Scilex Holding Company Financials

Annual	2023
Revenue:	$46.74M
Gross Profit:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2023
Revenue:	$46.74M
Gross Profit:	$26.92M (57.58 %)
EPS:	$-0.880

FY	2022
Revenue:	$38.03M
Gross Profit:	$27.24M (71.61 %)
EPS:	$-0.170

Financial Reports:

No articles found.

Scilex Holding Company

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.